Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mood swings

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Mood swings. Displaying page 1 of 1.
    EudraCT Number: 2004-004004-20 Sponsor Protocol Number: UI04/6748 Start Date*: 2005-09-26
    Sponsor Name:University of Leeds
    Full Title: A Randomised, Double-blind, Placebo Controlled trial to test the efficacy of St John's Wort (Hypericum Perforatum) for Premenstrual Syndrome.
    Medical condition: The 'premenstrual syndrome' is a cyclical condition occurring 7-10 days before the onset of menstruation, and is relieved at, or shortly after commencement of menstrual flow. The most commonly repo...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004516-22 Sponsor Protocol Number: 04-4025 Start Date*: 2005-02-01
    Sponsor Name:Uppsala University
    Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004483-22 Sponsor Protocol Number: 35664 Start Date*: 2013-11-29
    Sponsor Name:Mental Health Service, Esbjerg
    Full Title: NACOS - The effect of N-acetylcystein for depressive symptoms in patients with bipolar depression - A double blind randomized placebo-controlled trial with follow up
    Medical condition: Bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005336-25 Sponsor Protocol Number: DMKS-2011 Start Date*: 2012-03-23
    Sponsor Name:Chemische Fabrik Kreussler & Co. GmbH
    Full Title: A randomiszed, mono-center, placebo-controlled, double-blind, comparative study to evaluate the efficacy and safety of Dynexan® Mundgel in minors with acute painful sites of the mouth.
    Medical condition: Painful sites in the mouth
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000867-21 Sponsor Protocol Number: NGAM-13 Start Date*: 2021-08-16
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
    Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002174-58 Sponsor Protocol Number: ACT6796 Start Date*: 2007-11-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome
    Medical condition: Patients suffering from Obstructiv-Sleep Apnea Hypopnea Syndrome (OSAHS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:50:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA